| Project/Area Number |
22K09932
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 57020:Oral pathobiological science-related
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
Cueno Marni 日本大学, 歯学部, 専修研究員 (20569967)
|
|---|
| Project Period (FY) |
2022-04-01 – 2025-03-31
|
| Project Status |
Granted (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2024: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2023: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2022: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | SARS-CoV-2 spike / influenza HA / gingival vaccination / protein modelling / SARS-CoV-2 / influenza hemagglutinin / vaccine / SARS CoV 2 / Influenza |
|---|
| Outline of Research at the Start |
Research Activity 1: Virulence factor entry through the gingival crevice can affect the body systemically by altering immune-related and ageing-related biochemical networks.
Research Activity 2: Virulence factor entry through the gingival crevice can affect the brain and nerve cells in vivo.
Research Activity 3: Identifying target amino acid residues in the SARS CoV 2 spike and influenza A/B hemagglutinin proteins that could affect structural evolution
and viral infection among seasonal and pandemic influenza strains.
Research Activity 4: Vaccination design and antigen production strategies.
|
| Outline of Annual Research Achievements |
We were able to design the molecular structures related to the following: SARS-CoV-2 spike protein, influenza A H3N2 hemagglutinin (HA) and H5N1 HA, and influenza B/Yamagata HA proteins. Additionally, we were also able to do in silico xanthan gel molecular docking and confirmed that protein epitopes associated with activating B- and T-cell immune responses are readily exposed after xanthan gel molecule docking. We were able to optimize the antigen:gel ratio for influenza A H3N2 HA, H5N1 HA, and influenza B/Yamagata HA while antigen:gel ratio optimization for SARS-CoV-2 spike proteins are on-going.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
We successfully designed and produced all our desired target antigen proteins (SARS-CoV-2 alpha, beta, gamma, delta, omicron spike proteins, influenza A H3N2 HA, influenza A H5N1 HA, influenza B/Yamagata HA) in silico. Additionally, antigen:gel ratio optimization for influenza A H3N2 HA, influenza A H5N1 HA, influenza B/Yamagata HA were done while antigen:gel ratio optimization for SARS-CoV-2 alpha, beta, gamma, delta, and omicron spike proteins are on-going. Three manuscripts have been written and submitted to internationally peer-reviewed journals and are currently under review.
|
| Strategy for Future Research Activity |
Vaccination of the optimized antigen:gel ratio along the gingival crevice will be performed. ELISA (B-cell immunity) and ELISPOT (T-cell immunity) will be performed following previously published work. Immune response from all all protein antigens (SARS-COV-2 spike, influenza A HA, and influenza B HA) will be checked to establish immune efficacy of the gel vaccine. In addition, results will be compared to direct gingival, sublingual, oral, and intramuscular vaccination strategies.
|
